ATE510214T1 - Krankheitsdiagnose - Google Patents

Krankheitsdiagnose

Info

Publication number
ATE510214T1
ATE510214T1 AT01998835T AT01998835T ATE510214T1 AT E510214 T1 ATE510214 T1 AT E510214T1 AT 01998835 T AT01998835 T AT 01998835T AT 01998835 T AT01998835 T AT 01998835T AT E510214 T1 ATE510214 T1 AT E510214T1
Authority
AT
Austria
Prior art keywords
disease diagnosis
disease
protease
diagnosis
adhesion
Prior art date
Application number
AT01998835T
Other languages
English (en)
Inventor
Rachid Tazi-Ahnini
Claes Bavik
Simon Ward
Gordon Duff
Michael Cork
Original Assignee
Crawford Healthcare Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0029225A external-priority patent/GB0029225D0/en
Priority claimed from GB0029879A external-priority patent/GB0029879D0/en
Application filed by Crawford Healthcare Holdings Ltd filed Critical Crawford Healthcare Holdings Ltd
Application granted granted Critical
Publication of ATE510214T1 publication Critical patent/ATE510214T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rehabilitation Therapy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01998835T 2000-11-30 2001-11-30 Krankheitsdiagnose ATE510214T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0029225A GB0029225D0 (en) 2000-11-30 2000-11-30 Skin disease diagnosis and treatment
GB0029879A GB0029879D0 (en) 2000-12-07 2000-12-07 Skin disease diagnosis and treatment
PCT/GB2001/005303 WO2002044736A2 (en) 2000-11-30 2001-11-30 Diagnosis and treatment of epidermal or skin diseases

Publications (1)

Publication Number Publication Date
ATE510214T1 true ATE510214T1 (de) 2011-06-15

Family

ID=26245355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998835T ATE510214T1 (de) 2000-11-30 2001-11-30 Krankheitsdiagnose

Country Status (8)

Country Link
US (2) US20040106120A1 (de)
EP (2) EP2357478A3 (de)
JP (1) JP2004524010A (de)
KR (1) KR20030067696A (de)
AT (1) ATE510214T1 (de)
AU (1) AU2085502A (de)
CA (1) CA2430473A1 (de)
WO (1) WO2002044736A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171771B1 (de) 1999-04-09 2005-06-29 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
EP1247861A4 (de) * 1999-12-06 2004-11-10 Hidetoshi Inoko Verfahren zur untersuchung der gemeinen psoriasis
JP4262479B2 (ja) * 2001-02-09 2009-05-13 トールビョルン・エーイェルルード Ｓｃｃｅ改変トランスジェニック哺乳動物およびヒト疾患のモデルとしてのそれらの使用
US7019194B2 (en) 2001-02-09 2006-03-28 Lennart Hansson SCCE modified transgenic mammals and their use as models of human disease
AU2004231740A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
WO2005075667A1 (en) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 7 (klk7)
KR101286833B1 (ko) * 2005-03-18 2013-07-17 가부시키가이샤 시세이도 편평상피세포암 관련 항원을 지표로 하는 피부 성상의 평가방법
JP2008545390A (ja) * 2005-05-19 2008-12-18 シナージェンズ バイオサイエンス リミティド 遺伝的多型を用いた肺癌を発達させるリスクの評価方法
WO2006123943A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
JP2009511572A (ja) * 2005-10-16 2009-03-19 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 炎症性皮膚疾患、障害または症状のための医薬組成物および診断方法
GB0604370D0 (en) * 2006-03-03 2006-04-12 Univ Dublin Markers for melanoma progression
US20090208985A1 (en) * 2006-03-17 2009-08-20 Chika Katagiri Method Of Evaluating Degree Of Skin Sensitivity Using Squamous Cell Carcinoma Antigen As An Indicator Thereof
AU2007261445B2 (en) 2006-06-19 2013-04-18 The Johns Hopkins University Single-molecule PCR on microparticles in water-in-oil emulsions
JP4676448B2 (ja) * 2007-01-22 2011-04-27 株式会社マルハニチロ水産 タンパク質分解酵素阻害因子発現増強剤及びそれを含む皮膚の保水率改善剤
WO2009045508A1 (en) * 2007-10-02 2009-04-09 Research Foundation Of City University Of New York Novel protein transduction domains derived from secretory leukocyte protease inhibitor
JP2010115178A (ja) * 2008-11-14 2010-05-27 Nippon Menaade Keshohin Kk 皮膚の炎症の予測方法及びその用途
FR2940976B1 (fr) * 2009-01-13 2017-11-03 Oreal Utilisation a des fins de criblage d'actifs anti-ages de formes solubles de la proteine de type desmogleine i
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
NO2504357T3 (de) 2009-11-23 2017-12-30
EP3046577A4 (de) * 2013-09-20 2017-04-05 Landegren, Nils Neuartiges autoantigen
GB201509134D0 (en) * 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2020349509A1 (en) * 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
EP4304732A1 (de) * 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7-antikörper, anti-klk5-antikörper, multispezifische anti-klk5/klk7-antikörper und verfahren zur verwendung
AU2025212440A1 (en) * 2024-01-25 2026-07-02 Lipotrue, S.L. Peptides and cosmetic compositions for use in the treatment of acne and its related skin conditions
CN118440967B (zh) * 2024-05-31 2025-02-07 内蒙古大学 一种具有抗菌活性的sprr2a原核表达系统及其构建方法和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
DE3484332D1 (de) 1983-02-10 1991-05-02 Matsushita Electric Industrial Co Ltd Porzellanzusammensetzung fuer spannungsabhaengigen nichtlinearen resistor.
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
NZ218336A (en) 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5190917A (en) * 1986-12-24 1993-03-02 John Lezdey Treatment of psoriasis
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
CA1339351C (en) 1987-10-15 1997-08-26 Michael S. Urdea Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5091302A (en) 1989-04-27 1992-02-25 The Blood Center Of Southeastern Wisconsin, Inc. Polymorphism of human platelet membrane glycoprotein iiia and diagnostic and therapeutic applications thereof
US5552285A (en) 1991-02-27 1996-09-03 New York University Immunoassay methods, compositions and kits for antibodies to oxidized DNA bases
WO1993001315A1 (en) 1991-07-01 1993-01-21 The Blood Center Of Southeastern Wisconsin PEN POLYMORPHISM OF HUMAN PLATELET MEMBRANE GLYCOPROTEIN IIIa AND DIAGNOSTIC AND THERAPEUTIC APPLICATION THEREOF
FR2690691B1 (fr) 1992-04-29 1999-02-12 Bio Merieux Procede d'amplification d'arn necessitant une seule etape de manipulation.
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US5922575A (en) 1994-04-18 1999-07-13 Mayo Foundation For Medical Education & Research Mutations in the katG gene useful for detection of M. tuberculosis
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5654139A (en) 1994-09-21 1997-08-05 The United States Of America As Represented By The Department Of Health And Human Services Allelic variation of the serotonin 5HT2c receptor
US5807678A (en) 1995-03-23 1998-09-15 Regents Of The University Of California Identification of gene mutations associated with congenital lipoid adrenal hyperplasia
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US5869242A (en) 1995-09-18 1999-02-09 Myriad Genetics, Inc. Mass spectrometry to assess DNA sequence polymorphisms
JP2001510322A (ja) 1996-03-29 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア １８番染色体長腕（１８ｑ）上のマーカーに相関する両極性気分障害の治療法
US5955266A (en) 1996-04-01 1999-09-21 The Johns Hopkins University School Of Medicine Use of platelet polymorphism P1A2 to diagnose risk of thrombotic disease
US5691145A (en) 1996-08-27 1997-11-25 Becton, Dickinson And Company Detection of nucleic acids using G-quartets
US5691153A (en) 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
DE19813317A1 (de) 1998-03-26 1999-09-30 Roche Diagnostics Gmbh Verbessertes Verfahren zur Primer Extension Präamplifikations-PCR
CA2312075A1 (en) * 1998-11-05 2001-12-22 Protease Sciences, Incorporated Cosmetic compositions containing human type serine protease inhibitors
GB9906993D0 (en) * 1999-03-26 1999-05-19 Univ Leicester Psoriasis
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus

Also Published As

Publication number Publication date
US20040106120A1 (en) 2004-06-03
US20080292615A1 (en) 2008-11-27
CA2430473A1 (en) 2002-06-06
EP1356298B1 (de) 2011-05-18
EP1356298A2 (de) 2003-10-29
JP2004524010A (ja) 2004-08-12
WO2002044736A3 (en) 2003-08-28
EP2357478A3 (de) 2011-11-16
KR20030067696A (ko) 2003-08-14
EP2357478A2 (de) 2011-08-17
AU2085502A (en) 2002-06-11
WO2002044736A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AU2085502A (en) Diagnosis and treatment of disease
DK1694847T3 (da) Serinproteaser, nucleinsyrer kodende for serinenzymer og vektorer og værtsceller omfattende disse.
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
DK2236600T3 (da) Phytaser
ATE444377T1 (de) Nukleinsäurecharakterisierung
DE69939945D1 (de) Verfahren zur isolierung von stammzellen
DK1226271T3 (da) DNA-sekventeringsmetode
DE60322880D1 (de) Einfache katalytische dna-biosensoren für ionen auf grundlage von farbveränderungen
AU2002365421A1 (en) Methods and compositions for detecting the activation state of the multiple proteins in single cells
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
ATE456678T1 (de) Nukleinsäurenachweisverfahren mit erhöhter empfindlichkeit
EP1601779A4 (de) Carbonsäurereduktase-polypeptid, dieses codierende nukleotidsequenz und verwendungsverfahren
FI20031436L (fi) Menetelmä sydämen lyöntien tunnistamiseksi ja siitä saatavien suureiden laskemiseksi
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
DK1495112T3 (da) Cellekulturmedium
ATE439441T1 (de) Veränderte, fluoreszierende proteine
MEP27908A (en) Signal sequences for the production of leu-hirudine via secretion by e. coli in a culture medium
ATE307142T1 (de) Zweifarbiges fluorimetrisches proteaseassay
DK1248852T3 (da) Fremgangsmåde til vurdering af levedygtigheden af en celle
ATE538201T1 (de) Kcnb: ein kaliumkanalprotein
EP1141703A4 (de) Verfahren zum bestimmen eines erhöhten risikos einer frau ein "down-syndrom" zu tragen
WO2002086113A3 (en) Enzyme and snp marker for disease
EP1512740A4 (de) Von bacillus cereus produzierte cereulid-synthase, diese codierendes gen und verfahren zum nachweis von cereulid
ATE403863T1 (de) Verfahren zum nachweis von intrazellulären atp und/oder genexpression
WO2001031009A3 (en) Chandra: a th1-specific gene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties